SCHEDULE 13D: EcoR1 Capital Discloses Significant 27.9% Stake in iTeos Therapeutics

Investment firm EcoR1 Capital, LLC and its affiliates have disclosed a substantial 27.9% beneficial ownership stake in iTeos Therapeutics, Inc., acquired for investment purposes.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. have filed a Schedule 13D, disclosing their beneficial ownership in iTeos Therapeutics, Inc.
• EcoR1 Capital, LLC and Oleg Nodelman collectively beneficially own 10,688,978 shares of Common Stock, representing 27.9% of the outstanding shares.
• EcoR1 Capital Fund Qualified, L.P. beneficially owns 10,020,210 shares, representing 26.2% of the outstanding shares.
• These percentages are calculated based on 38,273,795 shares of Common Stock outstanding as of April 22, 2025.
• The shares were acquired using the Funds' working capital, with EcoR1 Capital Fund Qualified, L.P. investing $76,292,761.21 and EcoR1 Capital Fund, L.P. investing $5,092,225.41.
• The acquisition was made in the ordinary course of business for investment purposes, and the reporting persons have no present plans or proposals for corporate control changes or other significant actions related to the Issuer.
• The reporting persons may continue to evaluate their investment and may acquire or dispose of shares based on market conditions, company prospects, and other factors.

Sentiment

Score: 8

Explanation: The acquisition of a significant 27.9% stake by EcoR1 Capital, a specialized investment firm, indicates strong confidence in iTeos Therapeutics, Inc.'s current valuation and future prospects, despite the filing being for investment purposes without immediate plans for corporate control.

Positives

• A significant investment by a specialized investment firm (EcoR1 Capital) indicates confidence in iTeos Therapeutics, Inc.'s future prospects.
• The acquisition of a 27.9% stake by EcoR1 Capital, LLC and Oleg Nodelman demonstrates a strong commitment to the company.
• The substantial capital deployed ($76,292,761.21 by Qualified Fund and $5,092,225.41 by EcoR1 Capital Fund, L.P.) reflects a material investment.

Risks

• The document does not explicitly detail specific risks related to iTeos Therapeutics, Inc. beyond the general statement that future acquisitions or dispositions will depend on factors like the Issuer's business and prospects, industry conditions, and general market and economic conditions, implying inherent investment risks.

Future Outlook

The reporting persons state they have no present plans or proposals that relate to or would result in any of the actions described in Item 4(a) through (j) of Schedule 13D (e.g., changes in control, mergers, asset sales, changes in management, dividends, or other material changes). They may evaluate their investment on a continuing basis and may, from time to time, acquire or dispose of Common Stock depending on factors such as price, Issuer's business prospects, industry conditions, investment policies, other opportunities, and general market conditions.

Management Comments

• "The reporting persons have no present plans or proposals that relate to or would result in any of the actions described in Item 4(a) through (j) of Schedule 13D."
• "The reporting persons may evaluate on a continuing basis the investment in the Issuer and may, from time to time, acquire or dispose of Common Stock of the Issuer."
• "Any such acquisitions or dispositions will depend upon (i) the price and availability of the Issuer's securities; (ii) subsequent developments concerning the Issuer's business and prospects and the industry in which the Issuer operates; (iii) investment policies of the reporting persons; (iv) other investment opportunities available to the reporting persons; (v) general market and economic conditions; (vi) tax considerations; and (viii) such other factors as the reporting persons may deem relevant."

Industry Context

This filing indicates a significant investment by a specialized fund in a biotechnology company, iTeos Therapeutics, Inc. Such large stakes by investment firms often signal a belief in the long-term potential of the company's drug pipeline or strategic direction within the competitive biotechnology and pharmaceutical industry.

Related Party Transactions

• EcoR1 Capital, LLC acts as the investment adviser to investment funds, including EcoR1 Capital Fund Qualified, L.P., and is the general partner of these funds.
• Oleg Nodelman is the manager and control person of EcoR1 Capital, LLC.
• EcoR1 Capital, LLC is entitled to allocations and fees based on assets under management and realized/unrealized gains from its advisory role to the Funds.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a prominent investment firm could be viewed positively, potentially increasing investor confidence and influencing share price. It also signals a large, active shareholder with substantial voting and dispositive power.
• Management: The presence of a large, active investor like EcoR1 Capital could lead to increased scrutiny or engagement regarding strategic decisions, though the filing states no present plans for changes.

Next Steps

• The reporting persons may continue to evaluate their investment in iTeos Therapeutics, Inc.
• They may acquire additional shares or dispose of existing shares in the future, depending on various market and company-specific factors.

Key Dates

Keywords

iTeos Therapeutics, EcoR1 Capital, Oleg Nodelman, Schedule 13D, beneficial ownership, investment, common stock, biotechnology, pharmaceutical, healthcare, SEC filing